Table 4.
Influence of clinical factors on progression-free survival.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (<65/≥65years) | 1.662 (0.904-3.054) | 0.096 | ||
| Gender (Male/Female) | 1.131 (0.722-1.772) | 0.587 | ||
| Baseline ECOG PS (0/1/2) | 1.324 (0.903-1.941) | 0.342 | ||
| Site of primary tumor (Left side/Right side) | 1.262 (0.733-2.171) | 0.396 | ||
| Liver metastases (yes/no) | 0.531 (0.337-0.838) | 0.005 | 0.594 (0.363-0.973) | 0.038 |
| Lung metastases (yes/no) | 0.999 (0.639-1.561) | 0.995 | ||
| Peritoneum metastases (yes/no) | 0.992 (0.589-1.672) | 0.976 | ||
| Pelvic metastases (yes/no) | 1.601 (0.908-2.826) | 0.098 | ||
| Bone metastases (yes/no) | 0.817 (0.403-1.653) | 0.569 | ||
| Number of organs with metastases (≥2/<2) | 1.012 (0.582-1.761) | 0.966 | ||
| Treatment lines (3/>3) | 2.280 (0.706-7.366) | 0.154 | ||
| RAS status (wild/mutant) | 1.281 (0.764 -2.148) | 0.343 | ||
| BRAF status (wild/mutant) | 0.372 (0.113-1.222) | 0.090 | ||
| Prior antiangiogenic therapy (yes/no) | 0.422 (0.170-1.046) | 0.052 | ||
| Prior immunotherapy (yes/no) | 0.945 (0.452-1.978) | 0.880 | ||
| Prior antiangiogenic plus immunotherapy (yes/no) | 0.724 (0.346-1.511) | 0.382 | ||
| ALP (>160U/L/≤160U/L) | 0.390 (0.200-0.757) | 0.004 | 0.478 (0.241-0.948) | 0.035 |
| GGT (>50U/L/≤50U/L) | 0.788 (0.329-1.888) | 0.475 | ||
| LDH (>245U/L/≤245U/L) | 1.534 (0.643-3.675) | 0.213 | ||
| D-Dimer (>0.3mg/L/≤0.3mg/L) | 0.584 (0.371-0.918) | 0.020 | 0.783 (0.491-1.247) | 0.302 |
| FIB (>4g/L/≤4g/L) | 0.503 (0.314-0.807) | 0.004 | 0.517 (0.313-0.855) | 0.010 |
| TMB (TMB-H/TMB-L) | 0.988 (0.391-2.493) | 0.979 | ||
| Changes in ALP levels (decreased/did not decreased) | 1.743 (1.091-2.785) | 0.019 | 1.673 (1.040-2.690) | 0.034 |
| Changes FIB levels (decreased/did not decreased) | 1.138 (0.723-1.790) | 0.578 |
ECOG PS, Eastern Cooperative Oncology Group Performance Status; ALP, alkaline phosphatase; GGT, glutamyl transpeptidase; LDH, lactate dehydrogenase; FIB, fibrinogen; TMB, tumor mutational burden; TMB-H, high tumor mutational burden (≥10 mut/Mb); TMB-L, low tumor mutational burden (<10 mut/Mb).
Site of primary tumor, Left-side: distal 1/3 of transverse colon, descending colon, sigmoid colon and rectum, Right-side: proximal 2/3 transverse colon, cecum, ascending colon.
The bold values represent P<0.05, and the difference is statistically significant.